Technology | EP Mapping and Imaging Systems | January 19, 2018

Abbott Announces European Launch of Advisor HD Grid Mapping Catheter, Sensor Enabled

New device facilitates rapid, complex arrhythmia diagnosis and enables physicians to map any chamber of the heart to best determine ablation strategy and optimize patient care

Abbott Announces European Launch of Advisor HD Grid Mapping Catheter, Sensor Enabled

January 19, 2018 — Abbott last week announced CE Mark approval for the company's new Advisor HD Grid Mapping Catheter, Sensor Enabled, a product designed to advance cardiac mapping during cardiac ablation to treat patients with complex cardiac arrhythmias. With the European launch of this latest addition to Abbott’s electrophysiology portfolio, the company is offering physicians a mapping catheter with what it calls a first-of-its-kind grid configuration of electrodes for improved data collection that supports the creation of high-density mapping of cardiac tissue to support optimal treatment for patients.

For patients battling complex arrhythmias, physicians may use cardiac ablation therapy to create tiny scars or lesions on the heart to stop erratic electrical signals. Yet to ensure the best outcomes for their patients, physicians first need to identify which areas of the heart are responsible for those signals.  Mapping catheters are critical to providing this insight.

Indicated for use in any chamber of the heart, the Advisor HD Grid mapping catheter is designed to combat challenges sometimes associated with traditional mapping catheters.

Linear or circular mapping catheters may experience signal disruptions as the orientation of the catheter changes. The Advisor HD Grid mapping catheter is intended to help physicians avoid signal loss by allowing for data to be captured horizontally and vertically along a new electrode grid configuration with 16 sensors. As a result, the catheter utilizes high-density mapping to create detailed and anatomically accurate 3-D models of the heart.

Abbott's Advisor HD Grid mapping catheter enables physicians to collect data simultaneously along the catheter’s grid pattern to help optimize treatment decisions. Combined with the EnSite Precision Cardiac Mapping System, the data captured by the catheter is used to create a highly detailed map highlighting the differences between healthy tissue and tissue responsible for a patient's cardiac arrhythmias, such as atrial fibrillation. Such detail can make an important impact on a physician's ablation strategy and approach to patient care.

As an added benefit for physicians, by designing the Advisor HD Grid mapping catheter as Sensor Enabled, Abbott has allowed the catheter to capture data in two ways – through impedance and magnetic collection, improving how data is collected and providing physicians additional flexibility when pairing the catheter with the EnSite Precision Cardiac Mapping System.

For more information: www.sjmglobal.com

 


Related Content

News

April 26, 2026 — New results from the multicenter catheter ablation versus anti-arrhythmic drugs for Ventricular ...

Home April 29, 2026
Home
News

April 24, 2026 — Johnson & Johnson recently announced the initiation of the PERSIGMA randomized controlled trial (RCT) ...

Home April 27, 2026
Home
News

April 26, 2026 – New results from the pivotal multicenter trial FULCRUM-VT show that ultra-low temperature ablation ...

Home April 27, 2026
Home
News

April 13, 2026 — Johnson & Johnson has announced favorable 12-month interim effectiveness and safety results from ...

Home April 13, 2026
Home
News

In a milestone for Broward Health in Ft. Lauderdale, Fla., Jose L. Baez-Escudero, M.D., chief of cardiology and ...

Home March 24, 2026
Home
News

Feb. 6, 2026 — Abbott has announced new clinical data from two late-breaking presentations at AF Symposium in Boston ...

Home February 06, 2026
Home
News

Jan. 20, 2026 — Abbott has received CE Mark in Europe for the TactiFlex Duo Ablation Catheter, Sensor Enabled to treat ...

Home January 22, 2026
Home
News

Jan. 20, 2026 — Kardium Inc. has announced the publication of the PULSAR clinical trial results in the Journal of the ...

Home January 21, 2026
Home
Feature | Kyle Hardner

Robotic Magnetic Navigation (RMN) emerged two decades ago as an alternative approach to performing complex ablation ...

Home January 09, 2026
Home
News

Jan. 6, 2026 — Stereotaxis, a supplier of surgical robotics for minimally invasive endovascular intervention, has ...

Home January 06, 2026
Home
Subscribe Now